Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer

Hsiao Ching Chuang, Po Hsien Huang, Samuel K. Kulp, Ching Shih Chen

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)


The clear importance of mutated KRAS as a therapeutic target has driven the investigation of multiple approaches to inhibit oncogenic KRAS signaling at different molecular levels. However, no KRAS-targeted therapy has reached the clinic to date, which underlies the intrinsic difficulty in developing effective, direct inhibitors of KRAS. Thus, this article provides an overview of the history and recent progress in the development of pharmacological strategies to target oncogenic KRAS with small molecule agents. Mechanistically, these KRAS-targeted agents can be classified into the following four categories. (1) Small-molecule RAS-binding ligands that prevent RAS activation by binding within or outside the nucleotide-binding motif. (2) Inhibitors of KRAS membrane anchorage. (3) Inhibitors that bind to RAS-binding domains of RAS-effector proteins. (4) Inhibitors of KRAS expression. The advantage and limitation of each type of these anti-KRAS agents are discussed.

Original languageEnglish
Pages (from-to)370-376
Number of pages7
JournalPharmacological Research
Publication statusPublished - 2017 Mar 1

All Science Journal Classification (ASJC) codes

  • Pharmacology


Dive into the research topics of 'Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer'. Together they form a unique fingerprint.

Cite this